Psoriatic arthritis is an interminable joint pain that can affect the skin in wrist joint, outer joints of fingers and toes, lower back, knees, and ankles. It leads to inflammation in people with psoriasis, which can cause scaly red and white skin patches. Psoriatic arthritis can also affect the back and sacroiliac joints of the pelvis. Doctors are adopting nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), immunosuppressants, steroid injections, and joint replacement surgery to treat this disease. Technavio’s market research analysts have predicted that with the introduction of these treatments as some of the most promising approaches to treat psoriatic arthritis, the global psoriatic arthritis market will witness growth in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II drug development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the phase I and phase III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the pre-clinical stage.
Psoriatic arthritis drug development market report: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of psoriatic arthritis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
Therapeutic assessment of the drug development pipeline for psoriatic arthritis by route of administration
The subcutaneous route of administration (ROA) involves the administration of drug directly into the layer of the skin below the dermis and the epidermis. It has been observed that the majority of total therapeutics are being developed for subcutaneous administration.
Therapeutic assessment of the drug development pipeline for psoriatic arthritis by therapeutic modality
Recombinant fusion proteins
According to this pipeline analysis report, majority of the molecules that are currently in the drug development pipeline for psoriatic arthritis are being developed as monoclonal antibody. Monoclonal antibodies are made of identical immune cells that are clones of a parent cell.
Key questions answered in the report include
What are the drug development molecules in the various development stages for psoriatic arthritis?
What are the companies that are currently involved in the development of drug development molecules for psoriatic arthritis?
Insight into discontinued/inactive molecules with appropriate reasoning?
What are the major regulatory authorities approving drugs in various regions?
Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.